← Back to Clinical Trials
Recruiting NCT06815250

NCT06815250 Enhancing Maternal Vaccine Knowledge and Uptake: The InTroDuce-Programme Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06815250
Status Recruiting
Phase
Sponsor Universiti Putra Malaysia
Condition Vaccination Uptake
Study Type INTERVENTIONAL
Enrollment 351 participants
Start Date 2026-01-13
Primary Completion 2026-06

Trial Parameters

Condition Vaccination Uptake
Sponsor Universiti Putra Malaysia
Study Type INTERVENTIONAL
Phase N/A
Enrollment 351
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2026-01-13
Completion 2026-06
Interventions
Influenza and Tdap Vaccination Educational and Learning Module

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this InTroDuce-Programme interventional trial aims to test whether a web-based educational program can improve pregnant women's knowledge about Influenza and Tdap vaccinations and increase their intention to get vaccinated in the future. The main questions it aims to answer are: Does the InTroDuce-Programme increase knowledge and future intention of pregnant mothers to get vaccinated against Influenza and Tdap? How does demographic factors, attitudes and barriers affect vaccination decisions among pregnant mothers? Researchers will compare InTroDuce-Programme to standard care (routine antenatal care) to see if InTroDuce-Programme works to improve knowledge and future intention of pregnant mothers to be vaccinated against Influenza and Tdap. Participants will: Receive the web-based educational module (InTroDuce-Programme), which covers the importance, safety, and effectiveness of vaccinations, as well as addressing common concerns. Be followed up one month after the intervention. Answer questionnaires before and after the intervention to measure changes in vaccination knowledge and future intention to get vaccinated

Eligibility Criteria

Inclusion Criteria: * Pregnant women aged 18 years and older * Before or equal to 32 weeks of gestation as we need to follow-up the patients again at 36 weeks of gestation before delivery occurs. * Able to understand and consent to participation in the study. Exclusion Criteria: * Pregnant women with severe anaphylactic or allergic reactions to previous dose of influenza or Tdap vaccination. * Non-Malaysian

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology